Hydrocortisone plus fludrocortisone for adults with septic shock

New England Journal of Medicine

Volumn 378, Issue 9, 2018, Pages 809-818

  Annane, D ^a,b   Renault, A ^c   Brun Buisson, C ^d   Megarbane, B ^f   Quenot, J P ^k   Siami, S ^l   Cariou, A ^g   Forceville, X ^m   Schwebel, C ^a   Martin, C ^o   Timsit, J F ^a   Misset, B ^p   Ali Benali, M ^q   Colin, G ^r   Souweine, B ^s   Asehnoune, K ^u   Mercier, E ^a   Chimot, L ^w   Charpentier, C ^n,x   Francois B ^y   Boulain, T ^z   Petitpas, F ^aa   Constantin, J M ^t,ab   Dhonneur, G ⁱ   Baudin, F ^g   Combes, A ^j   Bohe J ^a   Loriferne, J F ^h,ac   Amathieu, R ^ad   Cook, F ^e   Slama, M ^a   Leroy, O ^af   Capellier, G ^e,ag   Dargent, A ^c,k   Hissem, T ^l   Maxime, V ^a   Bellissant, E ^c,v,ae   more..

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d Serv de Reanimation Med   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f HÔPITAL LARIBOISIÈRE   (France)

^g Université Paris Descartes ^*  (France)

^h UNIVERSITÉ PARIS DIDEROT   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j SORBONNE UNIVERSITÉ   (France)

^k DIJON UNIVERSITY HOSPITAL   (France)

^l Centre Hospitalier d'Etampes   (France)

^m UNIVERSITÉ DE RENNES 1   (France)

ⁿ GRENOBLE UNIVERSITY HOSPITAL   (France)

^o AIX MARSEILLE UNIVERSITY   (France)

^p HÔPITAL CHARLES NICOLLE   (France)

^q CENTRE HOSPITALIER DE VALENCIENNES   (France)

^r Centre Hospitalier de Vendée   (France)

^s SERVICE DE RHUMATOLOGIE   (France)

^t UNIVERSITÉ CLERMONT AUVERGNE   (France)

^u HÔTEL DIEU   (France)

^v CHU BRETONNEAU   (France)

^w Centre Hospitalier de Périgueux   (France)

^x UNIVERSITY HOSPITAL OF NANCY   (France)

^y DUPUYTREN UNIVERSITY HOSPITAL   (France)

^z CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^aa POITIERS UNIVERSITY HOSPITAL   (France)

^ab HOSPICES CIVILS DE LYON   (France)

^ac Hopital Saint Camille   (France)

^ad HÔPITAL JEAN VERDIER   (France)

^ae AMIENS UNIVERSITY HOSPITAL   (France)

^af CENTRE HOSPITALIER DE TOURCOING   (France)

^ag UNIVERSITY HOSPITAL OF BESANÇON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; FLUDROCORTISONE; HYDROCORTISONE; HYPERTENSIVE FACTOR; PLACEBO; ANTIINFLAMMATORY AGENT;

ADULT; ALL CAUSE MORTALITY; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL OUTCOME; DRUG EFFECT; FACTORIAL DESIGN; FEMALE; HOSPITAL DISCHARGE; HUMAN; HYPERGLYCEMIA; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; MULTICENTER STUDY (TOPIC); MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CAUSE OF DEATH; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; ORGAN DYSFUNCTION SCORE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RENAL REPLACEMENT THERAPY; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; SURVIVAL ANALYSIS;

AGED; ANTI-INFLAMMATORY AGENTS; CAUSE OF DEATH; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUDROCORTISONE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; ORGAN DYSFUNCTION SCORES; RECURRENCE; RENAL REPLACEMENT THERAPY; RESPIRATION, ARTIFICIAL; SHOCK, SEPTIC; SIMPLIFIED ACUTE PHYSIOLOGY SCORE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85042866565     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1705716     Document Type: Article

References (24)

1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 801-10.
2. Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315: 775-87.
3. Annane D, Sharshar T. Cognitive decline after sepsis. Lancet Respir Med 2015; 3:61-9.
4. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017;43:304-77.
5. Lilly announces withdrawal of Xigris following recent clinical trial results. Indianapolis: Eli Lilly, October 25, 2011 (https://investor.lilly.com/releasedetail2.cfm?ReleaseID=617602).
6. Sherkow JS. Patent law's reproducibility paradox. Duke Law J 2017; 66: 845-911.
7. Annane D. The role of ACTH and corticosteroids for sepsis and septic shock: an update. Front Endocrinol (Lausanne) 2016;7:70.
8. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating sepsis. Cochrane Database Syst Rev 2015;12:CD002243.
9. Volbeda M, Wetterslev J, Gluud C, Zijlstra JG, van der Horst IC, Keus F. Glucocorticosteroids for sepsis: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 2015; 41: 1220-34.
10. Bruno JJ, Dee BM, Anderegg BA, Hernandez M, Pravinkumar SE. US practitioner opinions and prescribing practices regarding corticosteroid therapy for severe sepsis and septic shock. J Crit Care 2012;27:351-61.
11. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
12. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-24.
13. Annane D, Buisson CB, Cariou A, et al. Design and conduct of the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial. Ann Intensive Care 2016;6:43.
14. Annane D, Timsit JF, Megarbane B, et al. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med 2013;187:1091-7.
15. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63-78.
16. Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 1998;26:1793-800.
17. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
18. Guide "100 recommandations pour la surveillance et la préventions des infections nosocomiales." Bulletin Epidémiologique Hebdomadaire. No. 48. November 30, 1992 (http://invs.santepubliquefrance.fr/beh/1992/48/index.html).
19. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007;370:676-84.
20. Goodwin JE, Feng Y, Velazquez H, Sessa WC. Endothelial glucocorticoid receptor is required for protection against sepsis. Proc Natl Acad Sci U S A 2013; 110: 306-11.
21. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor-kappaB- and glucocorticoid receptor alphamediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome: evidence for inf lammation-induced target tissue resistance to gluco-corticoids. Neuroimmunomodulation 2005; 12:321-38.
22. Keh D, Trips E, Marx G, et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 2016;316:1775-85.
23. Fadel F, André-Grégoire G, Gravez B, et al. Aldosterone and vascular mineralo-corticoid receptors in murine endotoxic and human septic shock. Crit Care Med 2017;45(9):e954-e962.
24. Polito A, Hamitouche N, Ribot M, et al. Pharmacokinetics of oral fludrocortisone in septic shock. Br J Clin Pharmacol 2016; 82:1509-16.